AzTrials
AzTrials

Preterm LabourNCT02351336

Fetal Adrenal Gland Volume Estimation Compared to Cervical Length Assessment in Prediction of Preterm Birth

An observational study of Preterm Labour, run by Wessam Magdy Abouelghar at 1 site in Egypt.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

If the investigators could prove that three -dimensional ultrasound measurement of fetal adrenal gland volume can accurately predict the likelihood of preterm birth in patients having symptoms and signs of PTL , they would be able to use it as a valuable component for assessment and early management of high risk… Read more about this study

Who is it for?
Ages 18 to 40 years, women only
Conditions the study is for
Preterm Labour
What is being tested?
Ultrasound imaging
Type of treatment
Medical device
How many people
78 participants
Where
1 siteEgypt
Study dates
Aug 2014to Feb 2015
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • Women only
  • No healthy volunteers
  • Adult

Study population: Women who are diagnosed as having threatened preterm labour based on the American college of obstetricians and gynaecologists guidelines (ACOG,2003) : * Presence of uterine contractions ( at least 4 in 20 minutes or 8 in 60 minutes ) * Cervical dilataion >1cm, \&/or * Cervical effacement ≥ 80%

Who may be able to join

  • Age : 18 - 40 years
  • Gestational age: 26 - 35 weeks , which is going to be calculated according to the date of last menstrual period \& confirmed by first trimester ultrasonography .
  • Women who are diagnosed as having threatened preterm labour based on the American college of obstetricians and gynaecologists guidelines (ACOG,2003) :
  • Presence of uterine contractions ( at least 4 in 20 minutes or 8 in 60 minutes )
  • Cervical dilataion >1cm, \&/or
  • Cervical effacement ≥ 80% 4. Women having one or more of the following:
  • Multifetal pregnancy .
  • Previous preterm labor or premature birth, particularly in the most recent pregnancy or in more than one previous pregnancy

Who cannot join

  • Suspected fetal growth restriction .
  • Preterm premature rupture of the membranes : confirmed by visualization of amniotic fluid vaginal pooling at the time of sterile speculum examination .
  • Patients with antepartum haemorrhage ( due to placental abruption \&/or placenta previa )
  • Presence of fetal anomalies incompatible with life. 5 - Patients who are not sure of dates

Trial locations and contacts

1 site in 1 country.

Wessam M Abouelghar, MD contact

002-01227460679

dr.awessam@gmail.com

Egypt1 site, 1 recruiting
  • Ain Shams Maternity Hospital

    Cairo

    Wessam M Abouelghar, MD, 002-01227460679, dr.awessam@gmail.com

    R

    Recruiting

Other trials in Egypt

About this study

Official title: Three - Dimensional Ultrasound Estimation of Fetal Adrenal Gland Enlargement Compared to Assessment of Cervical Changes Alone & Prediction of Impending Preterm Birth

If the investigators could prove that three -dimensional ultrasound measurement of fetal adrenal gland volume can accurately predict the likelihood of preterm birth in patients having symptoms and signs of PTL , they would be able to use it as a valuable component for assessment and early management of high risk pregnant women for PTB which can be positively reflected on the risk of neonatal morbidity and mortality in those patients.

Read the detailed description

Preterm birth ( PTB) is one of the leading causes of neonatal morbidity and mortality Early PTB (≤ 34 weeks' gestation) carries a 7-fold increased risk of Neonatal death . Following PTB, survivors can experience significant long term cognitive, behavioral, emotional, sensory, and motor deficits. Hence, there is growing interest in the identification of women who are at Risk for spontaneous PTB. Many biophysical and biochemical markers have been discovered to identify those women who are at risk for spontaneous PTB.

Unfortunately, none of the various maternal and fetal biomarkers such as:

cytokines, CRH, C-reactive protein, fetal fibronectin ,…. etc. are sufficiently sensitive or specific to be used alone or in combination to help decrease the rate of preterm births. Obviously, there's a need for an accurate method with high sensitivity and specificity for prediction of preterm labor. So that an appropriate management or referral to a higher center can be done to women likely to have PTB. Whereas unnecessary tocolytic therapy can be avoided in women who are unlikely to have PTB. Convincing data have shown that 2-dimensional (2D) ultrasound measurement of cervical length (CL) can identify women at risk for PTB.

Accordingly, CL is now widely used in clinical practice for risk estimation. However, as understanding of the mechanisms of preterm labor (PTL) have evolved, obstetricians have learned that, in some women, cervical shortening is a phenomenon that carries no increased risk for prematurity. Therefore, the search for early and accurate markers that distinguish between physiologic processes and abnormal activation of the labor cascade has been ongoing.

Literature has suggested that activation of the fetal hypothalamic-pituitary-adrenal axis play a crucial rule in commencement of labor. A previous study demonstrated that three -dimensional ultrasound measurement of fetal adrenal gland volume (AGV) may identify women at risk for impending PTB. In a more recent study receiver operator characteristics (ROC) curve analysis revealed that three -dimensional ultrasound measurement of (AGV) was superior to two-dimensional ultrasound measurement of (AGV) for anticipation of PTB within 7 days of the scan. The aim of this study is to investigate the utility of 3D fetal adrenal gland volume measurement in the early prediction of PTB and to determine whether these measurements could be combined with 2D ultrasound cervical assessment to improve the early prediction of PTB.

Conditions
Preterm Labour
Being tested
Ultrasound imaging
Keywords
Threatened preterm birth, Fetal adrenal gland volume, Fetal zone enlargement, Prediction of preterm birth
Medical subject headings
Obstetric Labor, Premature

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ultrasound imagingDevice

    1. - Fetal adrenal gland volume calculation using 3D ultrasound ( in mm3)
    2. - corrected adrenal gland volume calculation ( adrenal gland volume (mm3)/ estimated fetal weight (kg) )
    3. - CL measurement using 2D ultrasound ( in cm)
Study groups in NCT02351336
Study groupRoleWhat they receive
threatened preterm labourWomen who are diagnosed as having threatened preterm labour based on the American college of obstetricians and gynaecologists guidelines (ACOG,2003) : * Presence of uterine contractions ( at least 4 in 20 minutes or 8 in 60 minutes ) * Cervical dilataion >1cm, \&/or * Cervical effacement ≥ 80%
Receives: Device: Ultrasound imaging

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 1. Accurate prediction of impending preterm birth using 3D ultrasound estimation of fetal adrenal gland volume

    Measured: within 7 days of ultrasound scan

Secondary outcomes (1)
  1. Superiority of Adrenal gland volme estimation in prediction of preterm birth compared to cervical length measurement alone

    Measured: 7 days of ultrasound scan

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Jan 2015 (estimated)
  2. Study startAug 2014
  3. Primary completionFeb 2015 (estimated)
  4. Study completionFeb 2015 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
78 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02351336
Sponsor's protocol ID
PTB 012
Status last verified
Feb 2015
First submitted
22 Jan 2015
Last updated
18 Feb 2015
Results posted
No
Data monitoring committee
Yes

Publications

  • Turan OM, Turan S, Funai EF, Buhimschi IA, Campbell CH, Bahtiyar OM, Harman CR, Copel JA, Buhimschi CS, Baschat AA. Ultrasound measurement of fetal adrenal gland enlargement: an accurate predictor of preterm birth. Am J Obstet Gynecol. 2011 Apr;204(4):311.e1-10. doi: 10.1016/j.ajog.2010.11.034. Epub 2011 Feb 3.

    PubMed 21292230

Questions about this trial

What is this clinical trial studying?

An observational study of Preterm Labour, run by Wessam Magdy Abouelghar at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 18 Feb 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Wessam M Abouelghar, MD (002-01227460679, dr.awessam@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

1. Accurate prediction of impending preterm birth using 3D ultrasound estimation of fetal adrenal gland volume (time frame: within 7 days of ultrasound scan). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02351336, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2015; AzTrials last refreshed its copy on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in